ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0035

Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides

Loqmane Seridi1, Matteo Cesaroni1, Qingxuan Song2, Ashley Orillion1, Frédéric Baribaud1, Tatiana Ort1, Sheng Gao2, Tomas Parker3, James Chevalier3, Dan Levine3, Alan Perlman3 and Jarrat Jordan1, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, 3The Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University New York, NY, USA., New York, NY

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, interferon, Lupus nephritis, Natural Killer Cells, Nephritis

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Session Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Approximately 40% of SLE patients will develop Lupus Nephritis (LN), of which 10-30 % will progress to end-stage renal disease. To further understand LN pathogenesis, we conducted transcriptomic profiling of blood and kidney biopsy samples from LN patients, healthy control (HC), and from four other nephritides.

Methods: Blood and kidney biopsies from healthy subjects (n=28 and 20 respectively), LN (26,21), Diabetic Nephropathy (DN; 10,6), Hypertensive kidney disease (HT;8,3), Minimal change disease (MC; 7,4), and Membranous nephropathy (MB; 4,4) were collected under informed consent. Gene expression profiling was conducted using RNA-Sequencing (RNASeq). Genes differently expressed between any two conditions (FDR < 0.05) were identified and clustered into co-expressed signatures. 

Results: We detected 5 and 6 gene signatures in blood and kidney, respectively. The signatures were enriched in distinct biological pathways, including “Interferon Signaling,” “Natural killer cell-mediated cytotoxicity (NK_CMC),” and “Aquaporin-mediated transport (AMT).” When compared to HC, Gene Set Variation Analysis (GSVA) showed an increase of “Interferon Signaling” expression in LN (p = 2.8E-6) and DN (p= 0.0038) blood and in LN (p=8.7E-8), DN (p=3.8E-4), HT (p=0.018) and MB (p=0.018) kidney. In LN and HT blood, we observed a decreased enrichment of the NK_CMC signature (p =1E-13, p=6.3E-3). A bimodal enrichment was observed in DN and MC blood, and ~40% of those patients showed an expression level comparable to that of the LN population. Also, the NK_CMC signature was upregulated in LN (P=0.011) and DN (P=0.016) kidney. Finally, the AMT signature was downregulated in kidney in all indications compared to healthy (p< 0.05).

Conclusion: Co-expression clustering of dysregulated genes unveiled signatures enriched in distinct biological pathways in both blood and kidney of nephritides. IFN signature upregulation in blood was specific to LN and DN, with a more prominent signal observed in LN. The IFN signature was upregulated in the kidney in all indications except MC. An NK-mediated cytotoxicity gene signature was down-regulation in the blood of LN and HT and upregulated in the kidney of LN and DN, suggesting a possible role of NK mediated cytotoxicity in LN and DN pathogenesis.  A signature enriched in aquaporin-mediated transport genes was downregulated in the kidney and might reflect kidney damage. Although this analysis was adequately powered for LN, trends observed in other indications require further validation with larger cohorts.


Disclosure: L. Seridi, Janssen Research & Development, LLC, 1, 3; M. Cesaroni, Janssen Research & Development, LLC, 1, 3; Q. Song, Janssen Research & Development, LLC, Spring House, PA, USA, 3; A. Orillion, Janssen Research & Development, LLC, 1, 3; F. Baribaud, Janssen Research & Development, LLC, 1, 3; T. Ort, Janssen Research & Development, LLC, 1, 3; S. Gao, Johnson & Johnson, 3; T. Parker, None; J. Chevalier, None; D. Levine, None; A. Perlman, None; J. Jordan, Janssen Research & Development, LLC, 1, 3.

To cite this abstract in AMA style:

Seridi L, Cesaroni M, Song Q, Orillion A, Baribaud F, Ort T, Gao S, Parker T, Chevalier J, Levine D, Perlman A, Jordan J. Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/distinct-biological-pathways-in-both-blood-and-kidney-further-define-molecular-profiles-across-diverse-nephritides/. Accessed June 1, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-biological-pathways-in-both-blood-and-kidney-further-define-molecular-profiles-across-diverse-nephritides/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences